Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $408.00 Price Target at Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target trimmed by Morgan Stanley from $495.00 to $408.00 in a research note released on Friday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on ALNY. Stifel Nicolaus boosted their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Piper Sandler restated an “overweight” rating and set a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price for the company. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Finally, Royal Bank Of Canada reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $477.13.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $338.06 on Friday. The firm’s 50-day moving average price is $399.61 and its 200-day moving average price is $423.63. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a market cap of $44.66 billion, a PE ratio of 1,408.58 and a beta of 0.32. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,955 shares of company stock valued at $24,072,733 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Activest Wealth Management boosted its position in Alnylam Pharmaceuticals by 10,700.0% in the 4th quarter. Activest Wealth Management now owns 108 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 107 shares during the period. FengHe Fund Management Pte. Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $86,966,000. Wealthfront Advisers LLC grew its stake in Alnylam Pharmaceuticals by 36.0% in the fourth quarter. Wealthfront Advisers LLC now owns 18,254 shares of the biopharmaceutical company’s stock worth $7,259,000 after purchasing an additional 4,834 shares in the last quarter. Torren Management LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth $93,000. Finally, Mitsubishi UFJ Trust & Banking Corp raised its position in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 79,397 shares of the biopharmaceutical company’s stock valued at $31,572,000 after purchasing an additional 1,936 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Barclays initiated coverage with an overweight (positive) recommendation — new institutional attention and an overweight start can attract buyers and support the share price. Barclays Initiates Coverage on Alnylam
• Positive Sentiment: Bank of America lowered its price target from $529 to $462 but maintained a Buy rating (implies ~36.7% upside vs. current price), which is supportive versus a full downgrade. BofA PT cut to $462
• Positive Sentiment: HC Wainwright cut its target from $570 to $510 but kept a Buy rating (implies ~50.9% upside), another vote of confidence from a sell-side firm. HC Wainwright PT cut to $510
• Positive Sentiment: Alnylam outlined a new five‑year strategy, “Alnylam 2030,” and is projecting ~ $5.3B revenue for 2026 — strategic growth targets and a multi‑year plan can support investor confidence in long‑term upside. Alnylam projects 2026 revenue ~$5.3B
• Neutral Sentiment: Alnylam will webcast a conference call to discuss Q4 and full‑year 2025 results — standard corporate event that may move the stock depending on actual results and guidance. Webcast of Q4/FY2025 results
• Neutral Sentiment: Reported short‑interest data shows effectively zero reported short position (data appears inconsistent/placeholder); this item is unlikely to explain intraday moves. (Internal short‑interest report)
• Negative Sentiment: Morgan Stanley lowered its price target from $495 to $408 and moved to an Equal Weight rating — a visible downgrade in sentiment from a major bank which likely pressured the stock. Morgan Stanley PT cut to $408
• Negative Sentiment: Technical context: the stock is trading below both its 50‑day (~$401.57) and 200‑day (~$423.47) moving averages, which can amplify downside as trend‑following and momentum flows react.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.